HOWL Valuation

Werewolf Therapeutics Inc

Add to Watchlist

Advanced Chart

0.710

+0.056(+8.560%)

Overview
Forecast
Valuation

HOWL Relative Valuation

HOWL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HOWL is overvalued; if below, it's undervalued.

Historical Valuation

Werewolf Therapeutics Inc (HOWL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 24.43 is considered Undervalued compared with the five-year average of 24.82. The fair price of Werewolf Therapeutics Inc (HOWL) is between 0.94 to 1.71 according to relative valuation methord. Compared to the current price of 0.71 USD , Werewolf Therapeutics Inc is Undervalued By 24.74%.

Relative Value

Fair Zone

0.94-1.71

Current Price：0.71

24.74%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.43

P/B

Median3y

1.02

Median5y

1.18

-192.52

FCF Yield

Median3y

-46.04

Median5y

-37.96

Competitors Valuation Multiple

The average P/S ratio for HOWL's competitors is 6.81, providing a benchmark for relative valuation. Werewolf Therapeutics Inc Corp (HOWL) exhibits a P/S ratio of 24.43, which is 258.74% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

HOWL.O

Werewolf Therapeutics Inc